Myriad Genetics Inc MYGN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EST
27.50UNCH (UNCH)
Volume
11,239
Close
27.50quote price arrow down-0.34 (-1.22%)
Volume
394,356
52 week range
9.24 - 31.60

...

Loading . . .

KEY STATS

  • Open27.95
  • Day High28.57
  • Day Low27.32
  • Prev Close27.84
  • 52 Week High31.60
  • 52 Week High Date02/25/21
  • 52 Week Low9.24
  • 52 Week Low Date03/18/20
  • Market Cap2.068B
  • Shares Out75.21M
  • 10 Day Average Volume0.81M
  • Dividend-
  • Dividend Yield-
  • Beta1.66
  • 1 Year % Change67.99

RATIOS/PROFITABILITY

  • EPS (TTM)-3.35
  • P/E (TTM)-8.22
  • Fwd P/E (NTM)-76.60
  • EBITDA (MRQ)-113.70M
  • ROE (MRQ)-25.55%
  • Revenue (MRQ)557.00M
  • Gross Margin (MRQ)68.03%
  • Net Margin (MRQ)-44.90%
  • Debt To Equity (MRQ)25.55%

EVENTS

  • Earnings Date05/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Myriad Genetics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a...
S. Louise Phanstiel CPA
Chairman
Paul Diaz J.D.
President
R. Bryan Riggsbee CPA
Chief Financial Officer
Paul Parkinson
Executive Vice President
Benjamin Jackson J.D.
Executive Vice President
Address
320 S Wakara Way
Salt Lake City, UT
84108-1214
United States